vs

Side-by-side financial comparison of 1stdibs.com, Inc. (DIBS) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $23.0M, roughly 1.6× 1stdibs.com, Inc.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -4.5%, a 0.9% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 0.9%). 1stdibs.com, Inc. produced more free cash flow last quarter ($3.6M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 2.0%).

1stdibs.com, Inc. is an American e-commerce company. It has an online marketplace, which sells luxury items such as high-end furniture for interior design, fine art and jewelry. The company has been recognized for "pushing the antiques business into the 21st century." Originally, founded in Paris, it is headquartered in New York City.

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

DIBS vs GYRE — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.6× larger
GYRE
$37.2M
$23.0M
DIBS
Growing faster (revenue YoY)
GYRE
GYRE
+32.6% gap
GYRE
33.4%
0.9%
DIBS
Higher net margin
GYRE
GYRE
0.9% more per $
GYRE
-3.7%
-4.5%
DIBS
More free cash flow
DIBS
DIBS
$9.4M more FCF
DIBS
$3.6M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
2.0%
DIBS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DIBS
DIBS
GYRE
GYRE
Revenue
$23.0M
$37.2M
Net Profit
$-1.0M
$-1.4M
Gross Margin
73.5%
95.3%
Operating Margin
-10.1%
0.3%
Net Margin
-4.5%
-3.7%
Revenue YoY
0.9%
33.4%
Net Profit YoY
80.0%
-340.1%
EPS (diluted)
$-0.02
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DIBS
DIBS
GYRE
GYRE
Q4 25
$23.0M
$37.2M
Q3 25
$22.0M
$30.6M
Q2 25
$22.1M
$26.8M
Q1 25
$22.5M
$22.1M
Q4 24
$22.8M
$27.9M
Q3 24
$21.2M
$25.5M
Q2 24
$22.2M
$25.2M
Q1 24
$22.1M
$27.2M
Net Profit
DIBS
DIBS
GYRE
GYRE
Q4 25
$-1.0M
$-1.4M
Q3 25
$-3.5M
$5.9M
Q2 25
$-4.3M
$1.6M
Q1 25
$-4.8M
$3.7M
Q4 24
$-5.2M
$569.0K
Q3 24
$-5.7M
$2.9M
Q2 24
$-4.4M
$4.5M
Q1 24
$-3.3M
$9.9M
Gross Margin
DIBS
DIBS
GYRE
GYRE
Q4 25
73.5%
95.3%
Q3 25
74.3%
94.7%
Q2 25
71.8%
95.7%
Q1 25
72.4%
95.9%
Q4 24
72.3%
95.8%
Q3 24
71.0%
96.2%
Q2 24
71.7%
96.9%
Q1 24
72.5%
96.4%
Operating Margin
DIBS
DIBS
GYRE
GYRE
Q4 25
-10.1%
0.3%
Q3 25
-21.3%
22.7%
Q2 25
-25.8%
8.1%
Q1 25
-27.7%
10.3%
Q4 24
-30.6%
2.4%
Q3 24
-34.9%
16.6%
Q2 24
-29.2%
12.7%
Q1 24
-24.3%
29.7%
Net Margin
DIBS
DIBS
GYRE
GYRE
Q4 25
-4.5%
-3.7%
Q3 25
-16.0%
19.4%
Q2 25
-19.5%
5.9%
Q1 25
-21.3%
16.9%
Q4 24
-22.9%
2.0%
Q3 24
-26.8%
11.2%
Q2 24
-20.0%
18.0%
Q1 24
-15.0%
36.6%
EPS (diluted)
DIBS
DIBS
GYRE
GYRE
Q4 25
$-0.02
$-0.01
Q3 25
$-0.10
$0.03
Q2 25
$-0.12
$0.00
Q1 25
$-0.14
$0.00
Q4 24
$-0.14
$0.00
Q3 24
$-0.15
$0.01
Q2 24
$-0.12
$0.01
Q1 24
$-0.08
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DIBS
DIBS
GYRE
GYRE
Cash + ST InvestmentsLiquidity on hand
$22.9M
$52.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$93.6M
$106.0M
Total Assets
$132.1M
$166.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DIBS
DIBS
GYRE
GYRE
Q4 25
$22.9M
$52.4M
Q3 25
$19.9M
$60.0M
Q2 25
$22.4M
$54.4M
Q1 25
$20.3M
$29.9M
Q4 24
$26.0M
$26.7M
Q3 24
$22.0M
$25.1M
Q2 24
$23.8M
$25.1M
Q1 24
$33.7M
$37.4M
Stockholders' Equity
DIBS
DIBS
GYRE
GYRE
Q4 25
$93.6M
$106.0M
Q3 25
$94.0M
$101.9M
Q2 25
$94.9M
$92.0M
Q1 25
$96.2M
$68.1M
Q4 24
$99.3M
$63.3M
Q3 24
$107.2M
$63.2M
Q2 24
$110.4M
$60.4M
Q1 24
$131.0M
$56.6M
Total Assets
DIBS
DIBS
GYRE
GYRE
Q4 25
$132.1M
$166.1M
Q3 25
$135.2M
$159.4M
Q2 25
$138.6M
$152.6M
Q1 25
$142.5M
$129.8M
Q4 24
$145.8M
$125.4M
Q3 24
$154.4M
$125.2M
Q2 24
$157.6M
$120.9M
Q1 24
$179.5M
$122.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DIBS
DIBS
GYRE
GYRE
Operating Cash FlowLast quarter
$4.3M
$-5.6M
Free Cash FlowOCF − Capex
$3.6M
$-5.8M
FCF MarginFCF / Revenue
15.7%
-15.5%
Capex IntensityCapex / Revenue
2.9%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-3.2M
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DIBS
DIBS
GYRE
GYRE
Q4 25
$4.3M
$-5.6M
Q3 25
$-1.5M
$4.7M
Q2 25
$-5.1M
$2.1M
Q1 25
$-96.0K
$-129.0K
Q4 24
$2.8M
$-2.8M
Q3 24
$-3.0K
$1.7M
Q2 24
$-2.6M
$-5.5M
Q1 24
$-3.1M
$2.9M
Free Cash Flow
DIBS
DIBS
GYRE
GYRE
Q4 25
$3.6M
$-5.8M
Q3 25
$-1.5M
$4.0M
Q2 25
$-5.2M
$1.8M
Q1 25
$-143.0K
$-251.0K
Q4 24
$1.5M
$-2.8M
Q3 24
$-44.0K
$1.0M
Q2 24
$-3.0M
$-6.9M
Q1 24
$-3.3M
$2.7M
FCF Margin
DIBS
DIBS
GYRE
GYRE
Q4 25
15.7%
-15.5%
Q3 25
-6.8%
13.1%
Q2 25
-23.4%
6.8%
Q1 25
-0.6%
-1.1%
Q4 24
6.5%
-10.1%
Q3 24
-0.2%
4.1%
Q2 24
-13.5%
-27.5%
Q1 24
-14.8%
9.8%
Capex Intensity
DIBS
DIBS
GYRE
GYRE
Q4 25
2.9%
0.4%
Q3 25
0.1%
2.2%
Q2 25
0.2%
1.0%
Q1 25
0.2%
0.6%
Q4 24
5.8%
0.2%
Q3 24
0.2%
2.7%
Q2 24
1.6%
5.8%
Q1 24
0.9%
0.9%
Cash Conversion
DIBS
DIBS
GYRE
GYRE
Q4 25
Q3 25
0.79×
Q2 25
1.32×
Q1 25
-0.03×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons